BioFocus signs compound management agreement with eMolecules, Inc.
BioFocus and eMolecules, Inc. announced that they have signed a compound management service agreement. Under the agreement eMolecules has selected Compound Focus, Inc., the BioFocus compound management operation located in South San Francisco, as its preferred partner for client compound order aggregation services.
Clients that order compounds from multiple vendors through the eMolecules platform will have the option to ship their compounds directly from the vendor to the Compound Focus facility where both liquid and solid samples will be reformatted into preferred storage containers, passed through analytical quality control and shipped to an agreed client destination.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Miele strengthens medical technology division with joint venture - The new company is one of the largest players on the global market
New study sheds light on evolution of 2009 pandemic influenza A(H1N1) virus in Japan
Celgene Announces New Drug Application Filing for REVLIMID in Japan

Clear Advantage™ | Reagent reservoirs | Integra Biosciences
Sanofi-aventis to acquire TargeGen Inc. - Development of oral potent oncology medicines for the treatment of hematological malignancies
Cardio3 BioSciences Announces Positive Outcome of the C-Cure Phase II Clinical Trial in Heart Failure Patients
